tiprankstipranks
Plus Therapeutics (PSTV)
NASDAQ:PSTV
US Market
PSTV
Plus Therapeutics
RESEARCH TOOLSreports
Want to see PSTV full AI Analyst Report?

Plus Therapeutics (PSTV) Stock Forecast & Price Target

1,720 Followers
See the Price Targets and Ratings of:

PSTV Analyst Ratings

Strong Buy
5Ratings
Strong Buy
4 Buy
1 Hold
0 Sell
Based on 5 analysts giving stock ratings to
Plus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PSTV Stock 12 Month Forecast

Average Price Target

$38.00
▲(6451.72% Upside)
Based on 5 Wall Street analysts offering 12 month price targets for Plus Therapeutics in the last 3 months. The average price target is $38.00 with a high forecast of $65.00 and a low forecast of $12.00. The average price target represents a 6451.72% change from the last price of $0.58.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","18":"$18","34":"$34","50":"$50","66":"$66"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,18,34,50,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.09,10.62153846153846,15.153076923076922,19.684615384615384,24.216153846153844,28.747692307692304,33.279230769230765,37.810769230769225,42.342307692307685,46.873846153846145,51.405384615384605,55.936923076923065,60.46846153846154,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.09,8.544615384615383,10.999230769230769,13.453846153846154,15.908461538461538,18.36307692307692,20.817692307692305,23.27230769230769,25.726923076923075,28.18153846153846,30.636153846153842,33.090769230769226,35.54538461538461,{"y":38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.09,6.544615384615384,6.999230769230769,7.453846153846154,7.908461538461538,8.363076923076923,8.817692307692308,9.272307692307692,9.726923076923077,10.181538461538462,10.636153846153846,11.090769230769231,11.545384615384616,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.252,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.192,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.752,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.624,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.945,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.575,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.572,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.807,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.49,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.895,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.09,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$65.00Average Price Target$38.00Lowest Price Target$12.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Lake Street Analyst forecast on PSTV
Chad Messer
Lake Street
Lake Street
$50
Buy
8520.69%
Upside
Reiterated
05/19/26
Analysts' Top Healthcare Picks: Upstream Bio, Inc. (UPB), Plus Therapeutics (PSTV)
Maxim Group Analyst forecast on PSTV
Jason McCarthy
Maxim Group
Maxim Group
$12
Buy
1968.97%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV) and Iridex (NASDAQ: IRIX)
Ascendiant Analyst forecast on PSTV
Edward Woo
Ascendiant
Ascendiant
$65
Buy
11106.90%
Upside
Reiterated
04/08/26
We are maintaining our 2026 estimates for revenue (grant and CNSide revenue) of $4 million, but adjusting it for EPS to $(3.56) from $(3.22). Focus on RNL (REYOBIQ) for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda) (now called REYOBIQ), is being developed for recurrent glioblastoma (GBM) but has expanded to LM (leptomeningeal metastases) which is now the key focus of the company. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.
D. Boral Capital Analyst forecast on PSTV
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
03/31/26
Plus Therapeutics downgraded to Hold from Buy at D. Boral CapitalPlus Therapeutics downgraded to Hold from Buy at D. Boral Capital
H.C. Wainwright Analyst forecast on PSTV
Sean Lee CFA
H.C. Wainwright
H.C. Wainwright
$25
Buy
4210.34%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (NASDAQ: ACRS) and Plus Therapeutics (NASDAQ: PSTV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Lake Street Analyst forecast on PSTV
Chad Messer
Lake Street
Lake Street
$50
Buy
8520.69%
Upside
Reiterated
05/19/26
Analysts' Top Healthcare Picks: Upstream Bio, Inc. (UPB), Plus Therapeutics (PSTV)
Maxim Group Analyst forecast on PSTV
Jason McCarthy
Maxim Group
Maxim Group
$12
Buy
1968.97%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Plus Therapeutics (NASDAQ: PSTV) and Iridex (NASDAQ: IRIX)
Ascendiant Analyst forecast on PSTV
Edward Woo
Ascendiant
Ascendiant
$65
Buy
11106.90%
Upside
Reiterated
04/08/26
We are maintaining our 2026 estimates for revenue (grant and CNSide revenue) of $4 million, but adjusting it for EPS to $(3.56) from $(3.22). Focus on RNL (REYOBIQ) for oncology: The company is focused on its clinical stage oncology pipeline. The lead drug is a Rhenium-186-chelated NanoLiposome (Rhenium (186Re) Obisbemeda) (now called REYOBIQ), is being developed for recurrent glioblastoma (GBM) but has expanded to LM (leptomeningeal metastases) which is now the key focus of the company. Glioblastoma is a rare, incurable, and fatal brain cancer with no good treatment options. RNL is currently being evaluated in a NIH/NCI-supported Phase 2 clinical trial in the U.S. RNL is infused directly into the brain tumor to deliver very high therapeutic doses of radiation to patients whose cancer has recurred following treatments with surgery, chemotherapy, and radiation.
D. Boral Capital Analyst forecast on PSTV
Jason Kolbert
D. Boral Capital
D. Boral Capital
―
Hold
―
Downgraded
03/31/26
Plus Therapeutics downgraded to Hold from Buy at D. Boral CapitalPlus Therapeutics downgraded to Hold from Buy at D. Boral Capital
H.C. Wainwright Analyst forecast on PSTV
Sean Lee CFA
H.C. Wainwright
H.C. Wainwright
$25
Buy
4210.34%
Upside
Reiterated
03/16/26
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (NASDAQ: ACRS) and Plus Therapeutics (NASDAQ: PSTV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Plus Therapeutics

3 Months
Edward WooAscendiant
Success Rate
3/13 ratings generated profit
23%
Average Return
-12.85%
Copying Edward Woo's trades and holding each position for 3 Months would result in 23.08% of your transactions generating a profit, with an average return of -12.85% per trade.
1 Year
Edward WooAscendiant
Success Rate
1/13 ratings generated profit
8%
Average Return
-51.64%
Copying Edward Woo's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -51.64% per trade.
2 Years
Edward WooAscendiant
Success Rate
1/13 ratings generated profit
8%
Average Return
-62.65%
Copying Edward Woo's trades and holding each position for 2 Years would result in 7.69% of your transactions generating a profit, with an average return of -62.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PSTV Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
7
6
8
9
9
Buy
0
0
0
0
0
Hold
0
0
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
7
6
9
10
10
In the current month, PSTV has received 9 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. PSTV average Analyst price target in the past 3 months is 38.00.
Each month's total comprises the sum of three months' worth of ratings.

PSTV Financial Forecast

PSTV Earnings Forecast

Next quarter’s earnings estimate for PSTV is -$0.81 with a range of -$1.00 to -$0.46. The previous quarter’s EPS was -$1.05. PSTV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PSTV has Performed in-line its overall industry.
Next quarter’s earnings estimate for PSTV is -$0.81 with a range of -$1.00 to -$0.46. The previous quarter’s EPS was -$1.05. PSTV beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PSTV has Performed in-line its overall industry.

PSTV Sales Forecast

Next quarter’s sales forecast for PSTV is $1.04M with a range of $750.00K to $1.50M. The previous quarter’s sales results were $1.03M. PSTV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PSTV has Performed in-line its overall industry.
Next quarter’s sales forecast for PSTV is $1.04M with a range of $750.00K to $1.50M. The previous quarter’s sales results were $1.03M. PSTV beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PSTV has Performed in-line its overall industry.

PSTV Stock Forecast FAQ

What is PSTV’s average 12-month price target, according to analysts?
Based on analyst ratings, Plus Therapeutics’s 12-month average price target is 38.00.
    What is PSTV’s upside potential, based on the analysts’ average price target?
    Plus Therapeutics has 6451.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PSTV a Buy, Sell or Hold?
          Plus Therapeutics has a consensus rating of Strong Buy which is based on 4 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Plus Therapeutics’s price target?
            The average price target for Plus Therapeutics is 38.00. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $65.00 ,the lowest forecast is $12.00. The average price target represents 6451.72% Increase from the current price of $0.58.
              What do analysts say about Plus Therapeutics?
              Plus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.
                How can I buy shares of PSTV?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.